论文部分内容阅读
目的观察泮托拉唑联合托烷司琼治疗结直肠癌患者化疗相关性呕吐(CINV)的疗效与毒副反应。方法将采用m FOLFOX4方案化疗的结直肠癌患者60例,随机分为观察组和对照组各30例。观察组用泮托拉唑联合托烷司琼预防CINV,对照组单用托烷司琼,完成2周期化疗,对比2组预防呕吐疗效和毒副反应。结果 2组均未出现Ⅳ度呕吐反应,观察组呕吐发生率为30.0%(9/30)低于对照组的60.0%(18/30),中重度呕吐(Ⅱ度+Ⅲ度)发生率为10.0%(3/30)低于对照组的30.0%(9/30),差异均有统计学意义(P<0.05)。治疗中未观察到泮托拉唑和托烷司琼明显相关毒性。结论泮托拉唑联合托烷司琼能有效预防结直肠癌患者CINV,特别是能预防中重度呕吐患者与其防治化疗药物引起的药物性胃炎,安全性好。
Objective To observe the efficacy and side effects of pantoprazole and tropisetron in the treatment of chemotherapy-induced emesis (CINV) in patients with colorectal cancer. Methods Sixty patients with colorectal cancer treated with m FOLFOX4 regimen were randomly divided into observation group and control group with 30 cases each. In the observation group, the pantoprazole and tropisetron were used to prevent CINV. The control group was given tropisetron alone to complete 2 cycles of chemotherapy. The two groups were compared to prevent vomiting and toxicity. Results No grade Ⅳ vomiting was observed in both groups. The incidence of vomiting was 30.0% (9/30) in the observation group and 60.0% (18/30) in the control group. The incidence of moderate and severe vomiting (grade Ⅱ + Ⅲ) was 10.0% (3/30) lower than 30.0% (9/30) in the control group, the difference was statistically significant (P <0.05). No significant toxicity was associated with pantoprazole and tropisetron during the treatment. Conclusions Pantoprazole combined with tropisetron can effectively prevent CINV in patients with colorectal cancer, especially in patients with moderate-to-severe emesis and drug-induced gastritis caused by chemotherapy.